牛牛AI助理已提取核心訊息
On February 28, 2024, Arcutis Biotherapeutics, Inc., a Delaware-incorporated biopharmaceutical company, announced the entry into an underwriting agreement with Morgan Stanley & Co. LLC, Cowen and Company, LLC, and Guggenheim Securities, LLC, acting as representatives of the underwriters. The agreement pertained to a public offering of 15,789,474 shares of common stock at $9.50 per share. Additionally, the underwriters exercised an option to purchase 2,368,421 additional shares on February 29, 2024. The transaction was completed with the delivery of shares on March 4, 2024, resulting in net proceeds of approximately $161.6 million for Arcutis after accounting for underwriting discounts, commissions, and estimated offering expenses. The company plans to allocate the net proceeds towards the commercialization, development, and approval of its programs, including potential launches in atopic dermatitis and scalp psoriasis, expansion within psoriasis, as well as for working capital and other general corporate purposes. The offering was conducted under a shelf registration statement and included a preliminary prospectus supplement filed with the SEC on February 28, 2024, and a final prospectus supplement filed on March 1, 2024.
On February 28, 2024, Arcutis Biotherapeutics, Inc., a Delaware-incorporated biopharmaceutical company, announced the entry into an underwriting agreement with Morgan Stanley & Co. LLC, Cowen and Company, LLC, and Guggenheim Securities, LLC, acting as representatives of the underwriters. The agreement pertained to a public offering of 15,789,474 shares of common stock at $9.50 per share. Additionally, the underwriters exercised an option to purchase 2,368,421 additional shares on February 29, 2024. The transaction was completed with the delivery of shares on March 4, 2024, resulting in net proceeds of approximately $161.6 million for Arcutis after accounting for underwriting discounts, commissions, and estimated offering expenses. The company plans to allocate the net proceeds towards the commercialization, development, and approval of its programs, including potential launches in atopic dermatitis and scalp psoriasis, expansion within psoriasis, as well as for working capital and other general corporate purposes. The offering was conducted under a shelf registration statement and included a preliminary prospectus supplement filed with the SEC on February 28, 2024, and a final prospectus supplement filed on March 1, 2024.
2024年2月28日，特拉華州註冊的生物製藥公司Arcutis Biotherapeutics, Inc. 宣佈與摩根士丹利公司簽訂承保協議。有限責任公司、Cowen and Company, LLC和古根海姆證券有限責任公司擔任承銷商的代表。該協議涉及以每股9.50美元的價格公開發行15,789,474股普通股。此外，承銷商於2024年2月29日行使了額外購買2,368,421股股票的期權。該交易於2024年3月4日完成，股票交付，扣除承保折扣、佣金和預計發行費用後，Arcutis的淨收益約爲1.616億美元。該公司計劃將淨收益分配給其計劃的商業化、開發和批准，包括可能在特應性皮炎和頭皮牛皮癬領域推出、在牛皮癬領域擴張，以及用於營運資金和其他一般公司用途。此次發行是根據上架註冊聲明進行的，其中包括2024年2月28日向美國證券交易委員會提交的初步招股說明書補充文件和2024年3月1日提交的最終招股說明書補充文件。
2024年2月28日，特拉華州註冊的生物製藥公司Arcutis Biotherapeutics, Inc. 宣佈與摩根士丹利公司簽訂承保協議。有限責任公司、Cowen and Company, LLC和古根海姆證券有限責任公司擔任承銷商的代表。該協議涉及以每股9.50美元的價格公開發行15,789,474股普通股。此外，承銷商於2024年2月29日行使了額外購買2,368,421股股票的期權。該交易於2024年3月4日完成，股票交付，扣除承保折扣、佣金和預計發行費用後，Arcutis的淨收益約爲1.616億美元。該公司計劃將淨收益分配給其計劃的商業化、開發和批准，包括可能在特應性皮炎和頭皮牛皮癬領域推出、在牛皮癬領域擴張，以及用於營運資金和其他一般公司用途。此次發行是根據上架註冊聲明進行的，其中包括2024年2月28日向美國證券交易委員會提交的初步招股說明書補充文件和2024年3月1日提交的最終招股說明書補充文件。
有用
沒用